NR (Nicotinamide Riboside) · Evidence-First Fact Sheet
NR is a vitamin B3-derived NAD+ precursor converted through NRK1/NRK2 kinases into NMN and then NAD+. Human evidence anchors include Trammell 2016 first-in-human pharmacokinetics (PMID 27721479) and Martens 2018 chronic NR supplementation in older adults (PMID 29599478). The page summarizes mechanism, endpoints, dosing, regulatory status, and safety boundaries for educational use only.
1. Quick Summary
NR, or nicotinamide riboside, is a vitamin B3-derived NAD+ precursor. Its main consumer-relevant claim is not that it treats a disease, but that it can feed the NAD+ salvage pathway and raise NAD+ related metabolites in humans under studied conditions.
The two anchors for the current evidence review are Trammell 2016 (PMID 27721479), a first-in-human pharmacokinetic study, and Martens 2018 (PMID 29599478), a chronic supplementation study in older adults. They support short-term biological plausibility and tolerability, while leaving open the harder questions of long-term safety and clinical outcomes.
2. Overview
NR sits in the same NAD+ precursor family as NMN, niacinamide, niacin, NADH, and newer reduced precursors. It differs from NMN by entering the salvage pathway one step upstream: NR is phosphorylated into NMN, then adenylated into NAD+.
This makes NR a useful comparator in the NAD+ precursor cluster. The public evidence frame is evidence-first: biochemical endpoints are stronger than clinical endpoint claims, and head-to-head superiority claims against NMN remain unsupported.
3. Mechanism
NR is converted by nicotinamide riboside kinases NRK1 and NRK2 into NMN. NMNAT enzymes then convert NMN into NAD+, the coenzyme used by sirtuins, PARP enzymes, CD38-related metabolism, and mitochondrial redox systems.
The practical implication is that NR and NMN converge inside the salvage network. Any claim that one is categorically superior to the other needs direct comparative human evidence; this page does not treat mechanistic preference as clinical proof.
4. Benefits and Evidence Boundaries
NAD+ metabolite elevation: This is the strongest and cleanest human evidence domain for NR. Trammell 2016 established oral NR pharmacokinetic behavior in humans, while Martens 2018 supports chronic administration and NAD+ metabolite elevation in older adults.
Cardiovascular and cognitive surrogate framing: NR is often discussed around vascular markers, aging biology, and cognitive support. Those are research contexts, not disease-treatment claims. The current public card places NR in evidence tier A for the precursor family while keeping endpoint language conservative.
Longevity framing: No human NR trial has measured lifespan as an endpoint. Lifespan-extension claims are not supported by the two anchor PMIDs for this page.
5. Dosage
The public card range is 300-1000 mg/day, with Martens 2018 anchoring 1000 mg/day for six weeks in older adults. This is an evidence-review range, not a personal dosing recommendation.
Safety interpretation should stay bounded by the duration and populations studied. There are no adequate pregnancy, lactation, pediatric, or long-duration safety data, and users taking prescription medication should treat NR as a clinician-discussion item rather than a routine add-on.
6. Regulatory Status
The public NC card summarizes NR as FDA GRAS 2016 for NIAGEN and an accepted NDIN history, with European Novel Food authorization in 2019 for nicotinamide riboside chloride under specified adult-use limits. Brazil is presented under the dietary supplement framework without an Anexo V health claim.
Regulatory permission to market an ingredient is not the same thing as permission to make a disease or longevity outcome claim. Page copy and structured data therefore avoid disease-treatment language and keep claims tied to evidence anchors.
7. Cross-Link
For the direct NMN-versus-NR decision frame, read the long-form evidence article: NMN vs NR Decision Tree · Evidence-Anchored.
For broader precursor context, compare NMN, NADH, NMNH, and the NAD+ cluster hub.
8. FAQ
1. Does NR raise NAD+ in humans?
Yes for NAD+ related metabolites under studied conditions. The public anchors are Trammell 2016 (PMID 27721479) and Martens 2018 (PMID 29599478).
2. Is NR the same as NMN?
No. NR is a nucleoside and NMN is a nucleotide. NR is phosphorylated to NMN before NMN is converted into NAD+.
3. Is NR better than NMN?
No head-to-head human clinical endpoint trial establishes superiority. The safest public wording is that both feed the NAD+ salvage network through related steps.
4. Can NR support longevity?
NR is relevant to aging-biology research because NAD+ metabolism changes with age, but human lifespan or disease-prevention claims are not supported by the anchor evidence here.
5. Who should be cautious?
Pregnant or lactating people, children, adolescents, and people taking prescription medications should avoid self-directed NR supplementation unless a qualified clinician is supervising the decision.